Moody's: Allergan unchanged

Moody's Investors Service said that Allergan, Inc.'s A3 senior unsecured rating and Prime-2 short-term rating are not affected by the company's announcement of a $600 million settlement agreement with the Department of Justice related to Botox marketing practices.

The outlook is stable.

"The amount is absorbable within Allergan's liquidity profile and strong credit metrics and, therefore, does not pressure the A3 rating," said Moody's senior vice president Michael Levesque.

The last rating action on Allergan took place on April 4, 2006, when Moody's said it confirmed Allergan's A3/Prime-2 ratings, concluding a rating review for possible downgrade initiated on Nov. 15, 2005.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.